Anuh Pharma Ltd stands as a prominent producer of Active Pharmaceutical Ingredients (APIs), offering a range of bulk drugs and chemicals, including antibiotics, erythromycin salts, chloramphenicol, and various other chemicals. The company, which is affiliated with the SK Group, was established on February 19, 1960. Located in Tarapur, Maharashtra, their manufacturing facilities adhere strictly to cGMP standards and have received approvals from multiple multinational corporations.
Headquartered in Mumbai, the commercial hub of India, Anuh Pharma Ltd is recognized as an export house, catering to markets in Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore, and numerous other countries. Over the years, the company has undertaken significant expansions to enhance its production capabilities. For instance, in 2006-07, they inaugurated a new plant, thereby increasing their antibiotics production capacity from 400,000 kg to 600,000 kg. Subsequently, during 2008-09, they completed another expansion project, augmenting their installed capacity by 150 metric tons per annum, with commercial production commencing in September 2008.
Furthermore, the company has attained approvals for its products from the European Directorate for the Quality of Medicines & HealthCare (EDQM), facilitating their entry into European markets. Notably, in January 2010, Anuh Pharma Ltd secured approval for its product Erythromycin E.P., followed by approvals for Pyrazinamide in April 2010 and Clobetasol Propionate in June 2010, opening up avenues for sales in European countries for their own consumption.
Headquartered in Mumbai, the commercial hub of India, Anuh Pharma Ltd is recognized as an export house, catering to markets in Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore, and numerous other countries. Over the years, the company has undertaken significant expansions to enhance its production capabilities. For instance, in 2006-07, they inaugurated a new plant, thereby increasing their antibiotics production capacity from 400,000 kg to 600,000 kg. Subsequently, during 2008-09, they completed another expansion project, augmenting their installed capacity by 150 metric tons per annum, with commercial production commencing in September 2008.
Furthermore, the company has attained approvals for its products from the European Directorate for the Quality of Medicines & HealthCare (EDQM), facilitating their entry into European markets. Notably, in January 2010, Anuh Pharma Ltd secured approval for its product Erythromycin E.P., followed by approvals for Pyrazinamide in April 2010 and Clobetasol Propionate in June 2010, opening up avenues for sales in European countries for their own consumption.
